Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

UKALL14: Rituximab improves EFS in B-ALL, but four doses not enough

Key clinical point: Adding rituximab to chemotherapy appears to improve EFS in B-ALL, but more than four doses are needed.

Major finding: EFS rates were 41.9% and 48.7% with SOC and SOC+rituximab, a significant difference.

Study details: The randomized, phase 3 UKALL14 trial of 577 patients.

Disclosures: Dr. Fielding is a consultant for Amgen, Novartis, Pfizer, and Incyte.


Marks D et al. ASH 2019, Abstract 739.